Clinical Trial Update: An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia [Phase 2]

View source ↗

Summary

An open-label Phase 2 clinical trial evaluating CTI-1601 in Friedreich's ataxia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• CTI-1601

Snippet

Sponsor: Larimar Therapeutics, Inc. | Conditions: Friedreich Ataxia | Phase 2 | Status: RECRUITING